PI3K signaling governs BCR-dependent CLL cell proliferation and its inhibitors, such as idelalisib, have been approved for treatment, while novel inhibitors are still being developed [127]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.